-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the Shenwan industry, there are a total of 430 A-share listed pharmaceutical and biological companies
.
As of February 25, more than 240 pharmaceutical companies have disclosed their 2021 performance forecasts, accounting for more than half of the total
.
Judging from the estimated net profit of this batch of pharmaceutical companies, nearly 80% of the companies' net profit is expected to be positive, and the more outstanding performance is mainly concentrated in the fields of vaccines and testing
.
Among them, vaccine-related companies such as Zhifei Biology and CanSino, which have the highest net profit, have net profits of more than 2 billion yuan
.
The 2021 performance forecast shows that Zhifei Bio’s annual net profit is expected to exceed 10 billion yuan
.
Recently, the company has released a performance report, the net profit attributable to 10.
197 billion yuan, a year-on-year increase of 208.
88%
.
The company's main business is the research and development, production and sales of vaccines and biological products
.
Regarding the reasons for the growth in performance, the company stated in the report that during the reporting period, the company continued to focus on its business development goals, increased investment in research and development, and brought forth new ideas.
The sales of independent products and agency products continued to increase steadily.
Important financial indicators such as net profit have increased significantly over the same period of the previous year
.
At the end of January this year, CanSino estimated that the company's net profit in 2021 would be 1.
85 billion to 2 billion yuan, turning losses into profits
.
According to the company, this is mainly because Kwesa has obtained the conditional listing approval in China and emergency use authorization from many overseas countries during the reporting period, which has a positive impact on CanSino's main business income and net profit attributable to owners of the parent company.
.
In addition to Zhifei Bio and CanSino, the net profit of vaccine companies such as Olin Bio and Kangtai Bio is also expected to increase significantly year-on-year in 2021.
Among them, Olin Bio is due to the first group A group C meningococcal polysaccharide conjugate vaccine in 2021.
The second batch was released and put on the market, which brought a growth point to the company's profit
.
Regarding the development of the vaccine industry, CanSino once mentioned in the 2021 interim report that with the continuous introduction of national support policies for the research and development of innovative vaccines, the proportion of innovative vaccines in my country has continued to increase, and the level of domestic vaccine research and development and preparations has gradually improved.
It is expected to narrow the technological gap between domestic vaccines and international vaccines
.
The epidemic has prompted the development of the domestic vaccine industry.
In the future, companies with rich R&D pipelines, strict quality control and key vaccine products will have long-term development opportunities
.
Companies in the field of testing, such as Hotjing Bio and Oriental Bio, also performed very well
.
Among them, Rejing Bio is expected to achieve a net profit of 2 billion to 2.
35 billion yuan in 2021, a year-on-year increase of 1684.
65% to 1996.
97%, mainly due to the substantial increase in the demand for antigen detection reagents in Europe, Southeast Asia and other countries and regions in the second half of 2021.
A substantial increase in overseas testing reagent revenue has been achieved
.
Orient Bio is expected to achieve a net profit of 4.
72 billion yuan to 5.
12 billion yuan in 2021, a year-on-year increase of 181.
45% to 205.
31% compared with the same period of the previous year (statutory disclosure data)
.
In the view of Essence Securities, judging from the global situation, it is expected that the testing volume will continue to remain at a historically high level, the demand for overseas antigen testing market will increase, and the global nucleic acid testing market will rise accordingly
.
However, Sinolink Securities pointed out in the research report that in terms of risks, global epidemic mitigation and supply expansion are superimposed, and the volume and price of testing products will usher in a downward trend, or will face the risk of a deterioration of the competitive landscape and less-than-expected business expansion
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
As of February 25, more than 240 pharmaceutical companies have disclosed their 2021 performance forecasts, accounting for more than half of the total
.
Judging from the estimated net profit of this batch of pharmaceutical companies, nearly 80% of the companies' net profit is expected to be positive, and the more outstanding performance is mainly concentrated in the fields of vaccines and testing
.
Among them, vaccine-related companies such as Zhifei Biology and CanSino, which have the highest net profit, have net profits of more than 2 billion yuan
.
The 2021 performance forecast shows that Zhifei Bio’s annual net profit is expected to exceed 10 billion yuan
.
Recently, the company has released a performance report, the net profit attributable to 10.
197 billion yuan, a year-on-year increase of 208.
88%
.
The company's main business is the research and development, production and sales of vaccines and biological products
.
Regarding the reasons for the growth in performance, the company stated in the report that during the reporting period, the company continued to focus on its business development goals, increased investment in research and development, and brought forth new ideas.
The sales of independent products and agency products continued to increase steadily.
Important financial indicators such as net profit have increased significantly over the same period of the previous year
.
At the end of January this year, CanSino estimated that the company's net profit in 2021 would be 1.
85 billion to 2 billion yuan, turning losses into profits
.
According to the company, this is mainly because Kwesa has obtained the conditional listing approval in China and emergency use authorization from many overseas countries during the reporting period, which has a positive impact on CanSino's main business income and net profit attributable to owners of the parent company.
.
In addition to Zhifei Bio and CanSino, the net profit of vaccine companies such as Olin Bio and Kangtai Bio is also expected to increase significantly year-on-year in 2021.
Among them, Olin Bio is due to the first group A group C meningococcal polysaccharide conjugate vaccine in 2021.
The second batch was released and put on the market, which brought a growth point to the company's profit
.
Regarding the development of the vaccine industry, CanSino once mentioned in the 2021 interim report that with the continuous introduction of national support policies for the research and development of innovative vaccines, the proportion of innovative vaccines in my country has continued to increase, and the level of domestic vaccine research and development and preparations has gradually improved.
It is expected to narrow the technological gap between domestic vaccines and international vaccines
.
The epidemic has prompted the development of the domestic vaccine industry.
In the future, companies with rich R&D pipelines, strict quality control and key vaccine products will have long-term development opportunities
.
Companies in the field of testing, such as Hotjing Bio and Oriental Bio, also performed very well
.
Among them, Rejing Bio is expected to achieve a net profit of 2 billion to 2.
35 billion yuan in 2021, a year-on-year increase of 1684.
65% to 1996.
97%, mainly due to the substantial increase in the demand for antigen detection reagents in Europe, Southeast Asia and other countries and regions in the second half of 2021.
A substantial increase in overseas testing reagent revenue has been achieved
.
Orient Bio is expected to achieve a net profit of 4.
72 billion yuan to 5.
12 billion yuan in 2021, a year-on-year increase of 181.
45% to 205.
31% compared with the same period of the previous year (statutory disclosure data)
.
In the view of Essence Securities, judging from the global situation, it is expected that the testing volume will continue to remain at a historically high level, the demand for overseas antigen testing market will increase, and the global nucleic acid testing market will rise accordingly
.
However, Sinolink Securities pointed out in the research report that in terms of risks, global epidemic mitigation and supply expansion are superimposed, and the volume and price of testing products will usher in a downward trend, or will face the risk of a deterioration of the competitive landscape and less-than-expected business expansion
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
